Since the eNOS directly mediates both contractility and permeability in collecting lymphatic vessels impaired in metabolic disease, restoring lymphatic eNOS activity while inhibiting the aberrant NO production by activated immune cells (Torrisi et al., 2016) (Rehal et al., 2020) is an attractive pharmacological target in metabolic disease. The gene discussed is NOS3; the disease is metabolic disease.